Lab Space Crunch Threatens Scotland's Life Sciences and Space Growth

Scotland's dual ambition to become a global hub for life sciences innovation and a leading space industry player faces an unexpected bottleneck: a critical shortage of specialist laboratory space. New data reveals that mid-sized scale-up companies across both sectors are struggling to access affordable, flexible lab facilities—a constraint that risks undermining years of strategic investment and damaging the nation's competitive edge in high-value manufacturing and research.

The warning comes as Scotland's life sciences sector approaches a £25 billion annual economic contribution target, while the space industry accelerates satellite manufacturing, propellant development, and ground systems innovation. Both ecosystems depend on shared infrastructure: specialist lab facilities capable of handling sensitive materials, advanced instrumentation, and rigorous regulatory compliance. Yet across Scotland's innovation corridors—from Edinburgh's Bioquarter to Glasgow's Advanced Forming Research Centre and emerging clusters around Sutherland and Unst—the availability of move-in-ready, cost-effective lab space remains acutely constrained.

The Scale-Up Lab Crisis: Numbers and Impact

A forthcoming report from Scottish Enterprise signals alarm. Of 340 life sciences and advanced materials companies surveyed across Scotland in Q1 2026, 68% cited inadequate access to specialist laboratory space as a significant constraint on growth. For companies planning scale-up operations—those moving from seed or Series A funding into commercial manufacturing or expanded R&D—the picture is darker still: 81% reported difficulty securing suitable facilities within reasonable distance from supply chains, talent pools, or customer bases.

The implications ripple across both life sciences and space technology sectors. Life sciences companies working on pharmaceutical formulations, medical devices, and diagnostics require ISO-certified cleanrooms, biohazard containment, and validated analytical equipment. Space technology firms—particularly those developing satellite propulsion systems, composite materials, and thermal management solutions—face similar demands. Scottish Enterprise notes that a single analytical laboratory setup can cost £2–5 million, making shared facilities economically essential for companies with £500,000 to £10 million in annual revenue.

The shortage is not uniform. Edinburgh's city centre commands premium rents (£45–65 per square metre annually for lab space), while Glasgow's West End and South Side cluster around £35–50. In peripheral innovation zones—Stirling, Ayrshire, and the Highlands—costs drop to £15–30 per square metre, but availability of move-in-ready, validated facilities is sparse. This geographic mismatch forces growing companies into a Hobson's choice: pay premium rates in established clusters or relocate to cheaper regions with weaker talent and supply-chain ecosystems.

Space Tech and Life Sciences: Overlapping Infrastructure Needs

The space sector's laboratory requirements are often overlooked in broader infrastructure planning, yet they mirror and sometimes exceed those of life sciences. Consider the parallel demands:

• Materials Testing: Both sectors require tensile testing, thermal cycling chambers, and spectroscopy. Satellite composite manufacturers and pharmaceutical packaging developers compete for the same validation equipment.
• Cleanroom Manufacturing: Satellite assembly requires Class 6–8 cleanrooms to prevent microcontaminants damaging sensitive electronics. Medical device manufacturers require equivalent or higher standards. Shared facilities could drive economies of scale, but few exist.
• Propulsion and Chemical Analysis: Companies developing solid-rocket or liquid-rocket propulsion—including Skyrora, the Peebles-based rocket developer—require hazmat-certified labs for energetic material characterization. These labs are rare in Scotland.
• Environmental and Thermal Testing: Satellite systems must endure vibration, vacuum, and thermal extremes. Pharmaceutical products require equivalent stability data. Yet Scotland has only three major thermal-vacuum chambers accessible to commercial users.

The convergence of space and life sciences around shared lab infrastructure has prompted Highlands and Islands Enterprise to commission a sector-bridging study. Early findings suggest that coordinated development of "dual-use" facilities—labs certified for both pharmaceutical and aerospace work—could unlock significant capital efficiency. However, regulatory fragmentation (pharmaceutical labs fall under MHRA oversight; aerospace labs under CAA and ESA standards) complicates shared governance.

Geographic Hotspots and the Peripheral Innovation Gap

Scotland's existing lab infrastructure clusters tightly around Edinburgh and Glasgow, reflecting historic concentrations of university research and pharma headquarters. Edinburgh's Bioquarter houses roughly 45% of Scotland's commercial life sciences lab capacity, yet occupancy rates exceed 85%, leaving minimal buffer for new entrants. Glasgow's growing cluster around the Clyde Gateway and innovation districts offers some relief but still faces capacity constraints.

The spatial mismatch creates acute challenges for Scotland's emerging space clusters. SaxaVord Spaceport on Unst, Shetland, offers world-class launch infrastructure but relies on Inverness and Aberdeen for specialized lab services—a 300+ km round trip. Sutherland Spaceport at A'Mhoine in Assynt faces similar logistics challenges. Companies like Clyde Space, the Glasgow-based satellite manufacturer, have built proprietary labs, but smaller suppliers and startups lack capital for comparable investment.

The Highlands and Islands Enterprise commissioned a detailed infrastructure audit in early 2026, identifying five potential sites for mid-sized (3,000–8,000 square metre) mixed-use lab facilities serving both life sciences and space technology. Sites in Inverness, Stirling, and Ayrshire emerged as highest-priority candidates, each offering lower real estate costs, proximity to emerging talent pipelines, and reasonable distance from existing clusters. However, capital investment requirements—estimated at £12–18 million per facility—remain unfunded.

Regulatory and Certification Barriers

Beyond real estate economics, regulatory fragmentation compounds the lab shortage. A facility certifying for pharmaceutical development must meet MHRA (Medicines and Healthcare Products Regulatory Authority) standards. One serving aerospace requires CAA or ESA certification. Dual certification is possible but costly—estimated at an additional 15–20% of capital expenditure and 8–12 months of compliance work.

The UK Space Agency has signalled openness to streamlined dual-certification pathways under emerging space industry frameworks, but formal mechanisms remain absent. Scottish Enterprise is advocating for a pilot programme: designate two mid-sized facilities as "strategic dual-use research hubs," grant them phased certification by both MHRA and CAA, and offer 5-year capital grants to offset incremental compliance costs. Cost: approximately £4 million from Scottish public funds, offset by accelerated scaling and job creation across both sectors.

Corporate and Academic Responses

Recognising the crisis, several major actors have begun improvising solutions. University of Edinburgh and University of Glasgow are expanding industrial access to validated labs on a cost-recovery basis, but demand vastly outstrips capacity. Clyde Space has partnered with Aberdeen's materials testing centre to share excess capacity, a model other anchor tenants are beginning to replicate.

More ambitiously, Scottish Enterprise is backing a consortium bid—led by an Edinburgh real-estate firm, supported by Edinburgh Chamber of Commerce and Scottish Federation of Small Businesses—to develop a 6,000 square metre mixed-use lab campus in Leith by 2028. The £16 million project includes 20 modular lab units (250–500 square metres each), shared analytical suites, and cleanroom capacity. Rent is projected at £32 per square metre—competitive with Edinburgh, undercutting premium zones, and positioned to serve both life sciences and space-adjacent advanced materials firms.

Alba Orbital, the Midlothian-based satellite producer, has signalled interest in anchor-tenant status for the Leith project, seeking dedicated space for satellite payload integration and testing. This move underscores a critical insight: space companies increasingly view Scottish lab capacity not as a luxury but as a core operational dependency.

Policy and Investment Priorities Ahead

Policymakers face three interconnected decisions:

1. Funding Infrastructure: Scottish Government's £50 million life sciences investment strategy (2023–2030) must explicitly allocate 15–20% to lab space development, not just equipment or personnel. Current allocations emphasise advanced therapeutics and diagnostics but neglect physical infrastructure. Space sector funding similarly skews toward launch-site development and hardware; ground-based R&D infrastructure remains under-resourced.
2. Regional Rebalancing: Devolution of capital investment authority to HIE and regional chambers could unlock mid-sized facility development outside Edinburgh and Glasgow, reducing geographic concentration risk and supporting spaceport ecosystems in Shetland and Sutherland.
3. Regulatory Harmonisation: The UK Space Agency should commission a formal dual-certification framework for life sciences and aerospace labs, reducing compliance costs and timelines. Scotland could pilot this before UK-wide rollout, positioning itself as a model for cross-sector facility governance.

International Context and Competitive Risk

The lab shortage carries competitive implications. Germany's DLR (Deutsches Zentrum für Luft- und Raumfahrt) actively co-invests in shared lab infrastructure near major space clusters. The Netherlands' ESA facilities near Leiden include multipurpose materials labs serving both space and life sciences. France's Sophia Antipolis technology park integrates pharmaceutical, biotech, and aerospace labs within a planned innovation zone. Scotland risks falling behind as competitors strategically bind infrastructure investment to talent retention and sector growth.

The talent dimension is acute. Early-career scientists and engineers recruited to Scottish space and life sciences roles expect modern, well-equipped lab environments. Forcing them into substandard, overcrowded facilities or requiring frequent commutes to distant analytical services drives attrition to London, Cambridge, and overseas hubs. Retention of the £700 million+ annual talent investment (salaries, benefits, recruitment) hinges on infrastructure quality parity with peer regions.

Forward-Looking Analysis: A Critical 18-Month Window

Scotland's lab space crisis is not inevitable; it is a policy choice point. If Scottish Enterprise, HIE, and Scottish Government act decisively in the next 18 months—greenighting 2–3 mid-sized facilities, piloting dual-certification pathways, and ring-fencing lab infrastructure in sector strategies—the constraint can be relieved by 2028–2029. The window requires:

• Immediate capital allocation: £25–30 million for four strategic facility projects (Leith, Inverness, Stirling, Ayrshire), leveraging private sector co-investment.
• Regulatory fast-tracking: UK Space Agency and MHRA joint taskforce on dual-certification, completion by Q4 2026.
• Sector coordination: Quarterly roundtables linking Scottish Enterprise, HIE, space companies, life sciences firms, and universities to align demand forecasting with infrastructure planning.

Conversely, inaction locks Scotland into a self-limiting growth trajectory. Companies unable to access validated lab space will outsource critical R&D to more supportive regions, fragmenting intellectual property and suppressing job creation. The £25 billion life sciences target slides further out of reach. Space sector scaling stalls as propulsion, materials, and satellite developers seek facilities elsewhere.

The paradox is stark: Scotland boasts world-class research universities, skilled workforces, and strategic launch infrastructure. Yet the unglamorous, decidedly unglamorous lab facility—a 1970s-built cleanroom in an industrial estate—remains the binding constraint on innovation and growth. Fixing it is neither novel nor difficult. It requires sustained investment, regulatory clarity, and cross-sector coordination. The cost of delay far exceeds the cost of action.